NCT04963127

Brief Summary

Dual-Energy/Multi-Energy/Spectral-CT can visualize bone marrow edema associated with fractures, however, current scientific evidence is mostly derived from to retrospective analyses. Our prospective study systematically analyzes the diagnostic accuracy of the visualization of bone marrow edema by including patients who are scheduled for a CT scan to exclude or further characterize a fracture. After giving informed consent, the CT scan will be performed using a dose-neutral Dual-Energy-/Multi-Energy-/Spectral-CT acquisition technique. If the patient undergoes MRI of the same region within 7 days, this scan will be used as a gold-standard for bone marrow edema. This will allow the quantification of diagnostic accuracy.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
800

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jul 2021

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 5, 2021

Completed
10 days until next milestone

First Posted

Study publicly available on registry

July 15, 2021

Completed
Same day until next milestone

Study Start

First participant enrolled

July 15, 2021

Completed
3.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 31, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 31, 2025

Completed
Last Updated

November 22, 2023

Status Verified

November 1, 2023

Enrollment Period

3.9 years

First QC Date

July 5, 2021

Last Update Submit

November 21, 2023

Conditions

Keywords

Spectral CTMulti-Energy CTDual-Energy CTBone Marrow Edema

Outcome Measures

Primary Outcomes (1)

  • Diagnostic Accuracy of Dual-Energy/Multi-Energy/Spectral CT to detect bone marrow edema in comparison with MRI as the goldstandard.

    sensitivity, specificity and positive and negative likelihood ratios will be assessed

    MRI of the same region can be used for comparison if performed within 7 days

Study Arms (2)

Prospective Cohort

400 patients who are scheduled to undergo a clinically requested CT scan of parts of the skeleton using a Dual-Energy/Multi-Energy/Spectral acquisition mode to exclude or further define bone fractures.

Diagnostic Test: Computed Tomography of the skeleton using a Dual-Energy-/Multi-Energy-/Spectral acquisition mode

Retrospective Cohort

400 patients who had undergone a clinically requested CT scan of the skeleton in standard acquisition mode in the past to exclude or further define bone fractures.

Diagnostic Test: Computed Tomography of the skeleton using a conventional single-energy / non-spectral acquisition mode

Interventions

CT acquisition using a Dual-Energy / Multi-Energy / Spectral acquisition mode

Also known as: Spectral Imaging
Prospective Cohort

CT acquisition using a standard single energy / non-spectral acquisition mode

Retrospective Cohort

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients who are at least 18 years of age who are referred by the emergency department for a CT scan with the suspicion of a fracture.

You may qualify if:

  • clinical suspicion for a fracture AND
  • indication for CT confirmed by board-certified radiologist ('justified indication' according to German/European radiation protection law) AND
  • patient (is able to give informed consent and) has given informed consent.

You may not qualify if:

  • cardiorespiratory instability (as judged by the referring physician)
  • age \< 18 years
  • known or suspected pregnancy
  • known bone metastases of a malignant disease
  • known rheumatic disease
  • metal implants in the region to be scanned
  • surgical intervention over the last 12 months in the region to be scanned
  • contraindications for MRI

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Hospital Augsburg

Augsburg, Bavaria, 86156, Germany

RECRUITING

MeSH Terms

Conditions

Fractures, Bone

Condition Hierarchy (Ancestors)

Wounds and Injuries

Study Officials

  • Schwarz, MD

    University Hospital Augsburg

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
OTHER
Target Duration
7 Days
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 5, 2021

First Posted

July 15, 2021

Study Start

July 15, 2021

Primary Completion

May 31, 2025

Study Completion

May 31, 2025

Last Updated

November 22, 2023

Record last verified: 2023-11

Data Sharing

IPD Sharing
Will share

We plan to share individual participant data upon request (pending final approval by the data protection officer of the university hospital).

Shared Documents
STUDY PROTOCOL, SAP, ICF, CSR
Time Frame
Requests for sharing individual participant data will be considered at the time of publication of the first manuscript containing result data.
Access Criteria
We plan to share data on request at this point in time.

Locations